Etienne Mukanya Ndomba

Dr. Etienne Mukanya Ndomba

Virology, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
ELEddy Kinganda - Lusamaki
Eddy Kinganda - Lusamaki
LBLionel Kinzonzi Baketana
Lionel Kinzonzi Baketana
ENEtienne Mukanya Ndomba
Etienne Mukanya Ndomba
JBJulie Bouillin
Julie Bouillin
GTGuillaume Thaurignac
Guillaume Thaurignac
SMSteve Ahuka Mundeke
Steve Ahuka Mundeke
Human Mpox cases are increasingly reported in Africa, with the highest burden in the Democratic Republic of Congo (DRC). While case reporting on a clinical basis can overestimate infection rates, laboratory confirmation by PCR can underestimate them, especially on suboptimal samples like blood, commonly used in DRC. Here we used a Luminex-based assay to evaluate whether antibody testing can be complementary to confirm cases and to identify human transmission chains during outbreak investigations. We used left-over blood samples from 463 patients, collected during 174 outbreaks between 2013 and 2022, with corresponding Mpox and VZV PCR results. In total, 157 (33.9%) samples were orthopox-PCR positive and classified as Mpox+; 124 (26.8%) had antibodies to at least one of the three Mpox peptides. The proportion of antibody positive samples was significantly higher in Mpox positive samples (36.9%) versus negative (21.6%) (p < 0.001). By combining PCR and serology, 66 additional patients were identified, leading to an Mpox infection rate of 48.2% (223/463) versus 33.9% when only PCR positivity is considered. Mpox infections were as such identified in 14 additional health zones and 23 additional outbreaks (111/174 (63.8%) versus 88/174 (50.6%)). Our findings highlight the urgent need of rapid on-site diagnostics to circumvent Mpox spread.

23 February 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
MMMathy Matungala-Pafubel
Mathy Matungala-Pafubel
Junior Bulabula-PengeJunior Bulabula-Penge
Junior Bulabula-Penge
MMMeris Matondo-Kuamfumu
Meris Matondo-Kuamfumu
SESamy Esala
Samy Esala
EDIDI ATANI FRANCOISEDIDI ATANI FRANCOIS
EDIDI ATANI FRANCOIS
SASteve Ahuka-Mundeke
Steve Ahuka-Mundeke
Polio-associated paralysis is one of the diseases under national surveillance in the Democratic Republic of the Congo (DRC). Although it has become relatively rare due to control measures, non-polio paralysis cases are still reported and constitute a real problem, especially for etiological diagnosis, which is necessary for better management and response. From September 2022 to April 2023, we investigated acute flaccid paralysis (AFP) cases in Kinshasa following an alert from the Provincial Division of Health. All suspected cases and their close contacts were investigated and sampled. Among the 57 sampled patients, 21 (36.8%) were suspects, and 36 (63.2%) were contacts. We performed several etiological tests available in the laboratory, targeting viruses, including Poliovirus, Influenza virus, SARS-CoV-2, Enterovirus, and arboviruses. No virus material was detected, but the serological test (ELISA) detected antibodies against Chikungunya Virus, i.e., 47.4% (27/57) for IgM and 22.8% (13/57) for IgG. Among suspected cases, we detected 33.3% (7/21) with anti-Chikungunya IgM and 14.3% (3/21) of anti-Chikungunya IgG. These results highlight the importance of enhancing the epidemiological surveillance of Chikungunya.

27 April 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
Antoine Nkuba-NdayeAntoine Nkuba-Ndaye
Antoine Nkuba-Ndaye
NBNeraide Biai
Neraide Biai
AKAdolphe Kwakanaba-Mweze
Adolphe Kwakanaba-Mweze
David LUPANDE MwenebituDavid LUPANDE Mwenebitu
David LUPANDE Mwenebitu
TCTchass Chasinga-Buharanyi
Tchass Chasinga-Buharanyi
SASteve Ahuka-Mundeke
Steve Ahuka-Mundeke
This study aimed to assess mpox virus (MPXV) seroprevalence in South Kivu, Democratic Republic of the Congo, where a large mpox outbreak started at the end of 2023. A community-based surveys was conducted in urban (April–May 2023) and rural (July–August 2024) areas and a multiplex serological assay to detect anti-IgG against MPXV has been used. MPXV seroprevalence was 3.3% in the urban survey (n = 1174) and 8.3% in the rural survey (n = 981), with differences according to health zone (P = .004) after the mpox outbreak. This study shows temporal and geographic variation in MPXV seroprevalence and suggest potential spread of mpox in the general population in South Kivu.